
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is a rapidly growing company with a diverse range of products including NIPT, HCS, Signatera, and Prospera, with potential for continued growth and expansion. Its recent successes and focus on sustainability make it a strong candidate for long-term investment. With positive momentum and strong prospects for the future, this company is a favorable choice for investors looking for potential growth and returns in the personalized diagnostics market.
Bears say
Natera is facing increasing competition in the MRD landscape and persistent competitive intensity in the Women's Health market. The company's strong moat based on its reimbursement advantage is at risk as competitors may replicate Natera's reimbursement journey, resulting in increased competition and lower margins for Natera. Additionally, there is a downside risk if MRD penetration stalls or if competitors are perceived as a greater threat than expected. These factors could lead to a decrease in Natera's premium and a potential stock price decline.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares